Focusing on immune-related diseases and inflammation allows NovImmune to have core expertise and critical mass (people, methodology, network) in these fields

A.	Target selection (1) benefits from a unique network of academic contacts as well as from selected agreements with biotech companies. These contacts allow a choice of therapeutic targets that is better than industry standards in terms of medical relevance and novelty.
B.	Generation of fully human therapeutic antibodies (3) from both genetically engineered hu-mice (following immunisation) and antibody-display technology maximises the success rate of high-affinity antibodies against a variety of antigen targets. Access to both technologies is also above industry standard.
C.	Operational excellence: a) for functional screening (4) of monoclonal antibodies, including sophisticated high throughput methodology, b) extensive animal biology for in vivo validation (6) of therapeutic antibodies in multiple animal models of human diseases.
D.	Thorough biological validation, (6) anticipating efficacy and medical relevance of a therapeutic monoclonal antibody, has a major impact on lowering subsequent rate of clinical failure.
E.	Manufacturing of therapeutic monoclonal antibodies for clinical use represents a well known bottleneck. NovImmune has anticipated this issue and concluded an agreement with Lonza Biologics that guarantees GMP production (7) of its antibodies, not only for clinical trials but also for subsequent market supply. This GMP production agreement adds significant value to NovImmune’s MAb development platform. In addition, NovImmune is already assembling clinical teams of worldwide opinion leaders in specific immune-related disorders and inflammation for the clinical trials of NovImmune’s first two products.